David Wallace
Executive Editor
Having previously worked in the European chemicals industry, Dave has been with Generics Bulletin since 2010. Keeping a close eye on deals, corporate strategy and market developments in the off-patent sector, he also brings his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, with a particular interest in France where he has lived and studied in the past. A regular delegate to generics and biosimilars events and conferences as well as a frequent panel moderator, he maintains close links with industry representatives around the world. He also organizes and judges the annual Global Generics & Biosimilars Awards. In his spare time, he enjoys art and playing the piano.
Latest From David Wallace
Biocon Strikes Mexican Deal For Liraglutide
Biocon Limited has struck a “semi-exclusive” distribution and supply deal with Mexican player Medix for local rights to the Indian firm’s liraglutide generic rival to Saxenda.
A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets
Celebrating positive trial results for its long-acting injectable olanzapine, at the same time as reporting across-the-board growth for its generics business in Q1, Teva says it is pushing forward with its “pivot to growth” strategy almost a year after it was introduced by CEO Richard Francis.
Waverley Waves Goodbye To Generics As It Relinquishes ANDAs
Waverley Pharma has blamed deep discounting and heavy competition for its decision to step back from generics and focus entirely on novel drug development.
Who’s Hired? mAbxience Appoints A New CEO
Spain’s mAbxience has named a new CEO following the departure of former chief Emanuelle Lepine. Meanwhile, Biosimilars Canada has re-elected its chair and vice-chair, while Lupin has added a pair of independent directors to its board.
Teva Exits Japanese Generics With Plan To Sell Local Business
Teva is putting its Japanese generics business up for sale, in an exit from the country’s generics market that has led the Israeli firm to register a substantial impairment charge in Q1.
Dr Reddy’s Enters US With Second Oracea Generic
Dr Reddy’s has launched the second US rival to Oracea, shortly after Lupin introduced the first generic doxycycline 40mg capsules following a favorable district court ruling.